Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Editas

- PMLiVE

Study identifies hundreds of priority targets for cancer drug discovery

Researchers identified 370 priority drug candidates across 27 types of cancer

Cell and gene therapies as depicted via a DNA strand

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Avalere Health

- PMLiVE

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

Avalere Health

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Impetus Digital

- PMLiVE

Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline

Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology

- PMLiVE

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

CRISPR gene-editing in cancer patients is safe, according to new study

Patients had no side effects following CRISPR treatment

- PMLiVE

Europe urged to adapt faster to gene therapy challenges

Resistance to high prices, even with novel payment models

- PMLiVE

Amicus forms gene therapy manufacturing partnership with Catalent

Biotech invests to speed gene therapies into clinical trials

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links